Skip to content

Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health

A Unified Protocol to Address Sexual Minority Women's Minority Stress, Mental Health and Hazardous Drinking

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05509166
Acronym
EQuIP
Enrollment
274
Registered
2022-08-22
Start date
2023-02-01
Completion date
2027-08-01
Last updated
2026-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy Drinking, Mental Health Issue

Keywords

LGBTQ, Cognitive Behavioral Therapy

Brief summary

The purpose of this 2-arm randomized controlled trial is to assess the efficacy of a 10-session lesbian, gay, bisexual, transgender, and queer (LGBTQ)-affirmative cognitive-behavioral psychotherapy (CBT) delivered via telehealth in a large sample of sexual minority women (SMW) in New York, New Jersey and Pennsylvania. The investigators will assess whether the EQuIP (Empowering Queer Identities in Psychotherapy) treatment demonstrates significant reductions in heavy drinking (HD) and mental health symptoms (e.g., depression) compared to LGBTQ-affirmative treatment-as-usual.

Detailed description

The purpose of this study is to assess the efficacy of a 10-session LGBTQ-affirmative cognitive behavioral psychotherapy (CBT) delivered via telehealth in a large sample of sexual minority women (SMW) in New York, New Jersey and Pennsylvania. The treatment, EQuIP (Empowering Queer Identities in Psychotherapy), uses a CBT-based transdiagnostic approach to target the common cognitive, affective, and behavioral responses to minority stress that lead to mental and behavioral health disparities for sexual minority women. We will assess in a 2-arm randomized controlled trial (RCT) whether the EQuIP treatment demonstrates significant reductions in heavy drinking (HD) and mental health symptoms (e.g., depression) compared to LGBTQ-affirmative Treatment-As-Usual. The investigators will assess whether psychosocial mechanisms (e.g., emotion dysregulation) mediate reductions in heavy drinking and separately and identify whether EQuIP is differentially efficacious across key demographic factors.

Interventions

BEHAVIORALLGBTQ-affirmative Cognitive Behavioral Therapy

10-session LGBTQ-affirmative psychotherapy using CBT techniques

BEHAVIORALLGBTQ-affirmative Treatment-As-Usual

10-session LGBTQ-affirmative psychotherapy

Sponsors

Yale University
Lead SponsorOTHER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants will be immediately assigned to either condition. Outcome assessors will be masked to study condition.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. be 18 years of age or older 2. be fluent in English 3. self-identify as lesbian, bisexual, queer, pansexual, or other non-heterosexual identity 3\) report at ≥ 8 standard drinks/week, on average, in the past 30 days, OR report at least 2 heavy drinking days ( ≥ 4 drinks in one day) in the past 30 days 4) currently experience a Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 depression or anxiety disorder (screened initially using a cutoff of ≥ 2 on the Brief Symptom Inventory-4 and further confirmed by diagnostic interview via the DIAMOND) 5) report at least minimum motivation to reduce drinking (measured by the Readiness Ruler) 6) live in New York, New Jersey, and Pennsylvania and planning to stay for at least the next 4 months

Exclusion criteria

1. report current mental health treatment ≥1 day/mo 2. report having received any CBT in the past 3 months 3. report current alcohol or drug abuse treatment, except mutual self-help (e.g., Alcoholics Anonymous) 4. need alcohol detoxification indicated by ≥9 on Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) 5. exhibit active psychosis or active mania, as assessed by the Structured Clinical Interviews for DSM-5 Disorders (SCID) Psych Screen 6. exhibit active suicidality or active homicidality, as assessed by the SCID-Psych Screen 7. be currently legally mandated to attend treatment 8. demonstrate gross cognitive impairment, as assessed with the Telephone Interview for Cognitive Status

Design outcomes

Primary

MeasureTime frameDescription
Change in heavy drinkingBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe proportion of heavy drinking days will be assessed using a 30-day Timeline Followback. The Timeline Followback is a structured interview that will assess alcohol use over the past 30 days. Heavy drinking days are defined as those in which more than four drinks were consumed within a two-hour period.

Secondary

MeasureTime frameDescription
Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND)Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe (DIAMOND) is a semi-structured diagnostic interview based on the DSM-5 that enables non-clinicians to determine the presence and severity of mood, anxiety, and stress-/trauma-related disorders.
Depression Symptom SeverityBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Center for Epidemiological Studies - Depression Scale (CES-D) will be used to compute an overall depression score (sum of the 20 items, with Items 3, 11, 14, and 16 reverse-scored). A higher score will indicate more depressive symptomatology during the past week. The range of scores for this outcome is 0-60.
Anxiety Symptom SeverityBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Beck Anxiety Inventory (BAI) will be used to compute an overall anxiety score. Total score is calculated by finding the sum of the 21 items. Score of 0-21 = low anxiety; score of 22-36 = moderate anxiety; score of 36 and above = high anxiety. A higher score will indicate more depressive symptomatology during the past week. The range of scores for this outcome is 0-63.
Overall Depression Severity and Impairment Scale (ODSIS)Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Overall Depression Severity and Impairment Scale (ODSIS) will be used to compute an overall depression severity and impairment score. Total score is calculated using the sum of the 5 items. The range of scores for this outcome is 0-20.
Overall Anxiety Severity and Impairment Scale (OASIS)Baseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Overall Anxiety Severity and Impairment Scale (OASIS) will be used to compute an overall anxiety severity and impairment score. Total score is calculated using the sum of the 5 items. The range of scores for this outcome is 0-20.
PTSD symptomsBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD to monitor symptom change during and after treatment
Suicidal IdeationBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Suicidal Ideation Attributes Scale (SIDAS) is a 5-item self-report measure that assesses suicidal ideation with response options from 0 to 10. Total SIDAS scores are calculated as the sum of the five items, with controllability reverse scored. Total scores range from 0 to 50.
Mental Health Symptom Presence and SeverityBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Brief Symptom Inventory (BSI) measures current or past presence and severity of mental health symptoms. The self-report measure is rated on a scale of 0 (not at all) to 4 (extremely), with higher scores indicating more severe symptomatology.
Alcohol UseBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Patient Reported Outcomes Measurement Information System (PROMIS) Alcohol Use Short Form is a self-report questionnaire designed to measure alcohol use in the past 30 days. Participants respond to 7 questions on a scale of 1 (Never) to 5 (Almost Always), and the sum of the responses are converted to a t-score, with a higher score representing higher alcohol use
Effects of Alcohol UseBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Brief Comprehensive Effects of Alcohol Scale evaluates participants' outcome expectancy when drinking. The measure contains 38 items that are rated on a scale of 1 (Disagree) to 4 (Agree), with a higher sum indicating a higher level of effect in certain alcohol use domains.
Frequency of Alcohol UseBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Daily Drinking Questionnaire assesses the amount of drinks a participant consumes on a daily basis throughout the course of a week.
Alcohol Self-EfficacyBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Alcohol Abstinence Self-Efficacy Scale measures a participant's confidence in being able to avoid or abstain from alcohol. Participants rate 20 items on a scale of 1 (Not at all confident) to 5 (Extremely confident), with a higher score indicating higher confidence in being able to abstain from alcohol.
Drug Use and Drug-Related ProblemsBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Drug Use Disorders Identification Test (DUDIT) is a self-report measure designed to assess drug-related problems and drug use. Participants rate 11 items that can be scored on a scale of 0 to 4, with a higher sum representing more drug-related problems and dependency.
Cannabis Use and Cannabis-Related ProblemsBaseline, 4-month follow-up, 8-month follow-up, and 12-month follow-upThe Cannabis Use Disorder Identification Test (CUDIT) assesses self-reported cannabis use and problems related to cannabis use. Participants rate 10 items on varying scales, with a higher sum indicating higher cannabis use and related problems.

Countries

United States

Contacts

CONTACTJohn E Pachankis, PhD
John.Pachankis@yale.edu646-429-9407
CONTACTDanielle M Chiaramonte, PhD
Danielle.Chiaramonte@yale.edu708-334-8331
PRINCIPAL_INVESTIGATORJohn E Pachankis, PhD

Yale University

PRINCIPAL_INVESTIGATORTonda Hughes, PhD

Columbia University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 10, 2026